Benchmark Holdings PLC Notice of Q1 Results (7979A)

TIDMBMK

RNS Number : 7979A

Benchmark Holdings PLC

07 February 2022

Benchmark Holdings plc

("Benchmark" or the "Company")

Notice of Q1 Results

Webcast for analysts and institutional investors

Equity Development webcast for retail investors

Benchmark Holdings plc (AIM: BMK), the aquaculture health, advanced nutrition, and genetics business, will announce its Q1 results, for the period ended 31 December 2021, on Tuesday 22 February 2022.

Webcast for analysts and institutional investors at 9am UK time

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a webcast for analysts and institutional investors on that day at 9am UK time. To register your interest, please contact benchmark@mhpc.com .

Equity Development investor presentation for retail investors at 12pm UK time

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a separate webcast for retail investors and wealth managers at 12.00pm UK time. The webcast is free and open to all existing and potential shareholders. Questions can be submitted during the presentation to be addressed at the end.

To register for the event, please click here .

A recording of the event will be available afterwards here .

For further information please contact Hannah Crowe / Matt Evans: 020 7065 2692.

Enquiries

 
 For further information, please contact: 
  Benchmark Holdings plc                     Tel: 020 3696 0630 
  Trond Williksen, CEO 
  Septima Maguire, CFO 
  Ivonne Cantu, Investor Relations 
 
  Numis (Broker and NOMAD)                   Tel: 020 7260 1000 
  James Black, Freddie Barnfield, Duncan 
   Monteith 
 
  MHP Communications                         Tel: 020 3128 8990 
  Katie Hunt, Reg Hoare, Charlie Protheroe   benchmark@mhpc.com

About Benchmark

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORUPUACPUPPGQC

(END) Dow Jones Newswires

February 07, 2022 01:59 ET (06:59 GMT)

Benchmark (LSE:BMK)
Historical Stock Chart
From Jun 2024 to Jul 2024